AstraZeneca shares plunge after heart drug Wainua fails late-stage trial
AstraZeneca’s stock fell up to 10.6% in London on July 9, 2026, after its experimental heart drug Wainua, developed with Ionis Pharmaceuticals, failed a Phase III trial for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). The drug did not reduce deaths or heart-related emergencies versus a placebo over 140 weeks. The failure, rare for AstraZeneca, triggered a reassessment of its pipeline premium and raised doubts about its $80 billion 2030 sales target, though analysts say long-term growth remains intact.
Editorial summary awaiting refresh
Cross-source coverage
Wire timeline
AstraZeneca's Trial Failure Raises Questions About Its Pipeline Valuation Premium
AstraZeneca's late-stage trial failure for Wainua, a drug treating a rare heart disease, caused shares to drop 6.2% on July 9, 2026, their worst day in over two years. While analysts estimate the financial impact at only 2-4% of valuation, the market reaction suggests investors are reassessing the premium long assigned to AstraZeneca's pipeline. The company, under CEO Pascal Soriot, has a strong track record of successful trials, making this failure surprising. Analysts say the setback does not undermine the long-term growth story but raises the bar for proving it, particularly regarding the $80 billion sales target by 2030. The trial failure also comes amid other challenges including a China bribery probe and patent expirations.
US Top News and AnalysisAstraZeneca's Trial Failure Raises Questions About Its Pipeline Premium
AstraZeneca's late-stage trial failure for Wainua, a drug intended to treat a rare heart disease (ATTR cardiomyopathy), caused its shares to drop 6.2% on July 9, 2026, their worst single-day decline in over two years. While analysts estimate the financial impact of the failure at only 2-4% of valuation, the market reaction was more severe, suggesting investors are reassessing the premium they have long assigned to AstraZeneca's drug pipeline. Under CEO Pascal Soriot, the company has built a reputation for consistent late-stage trial success, making this failure surprising. The setback raises doubts about AstraZeneca's credibility and its ambitious $80 billion sales target by 2030, though most analysts maintain that the company's long-term growth story remains intact. The event highlights a shrinking margin for error as the company faces upcoming patent expirations and pipeline scrutiny.
US Top News and AnalysisAstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
AstraZeneca suffered a rare late-stage clinical trial failure for its drug Wainua, intended to treat a rare heart disease (ATTR cardiomyopathy). The failure sent shares down 6.2% on July 11, 2026, their worst single-day drop in over two years. While analysts estimate the financial impact at only 2-4% of valuation, the market reaction suggests investors are reassessing the company's pipeline credibility and premium valuation. AstraZeneca, under CEO Pascal Soriot, has long been seen as a consistent late-stage trial performer. The failure raises doubts about its ambitious $80 billion sales target by 2030, though most analysts maintain that the long-term growth story remains intact. The event highlights a shrinking margin for error for the pharma giant.
US Top News and AnalysisAstraZeneca Plunges After New Heart Disease Drug Fails Trial
AstraZeneca shares plunged on July 9, 2026, after its drug Wainua, developed with Ionis Pharmaceuticals, failed to meet its primary endpoint in a Phase III trial for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a rare and fatal heart disease. The stock fell as much as 10.6% in London, its largest intraday drop since 2017, and closed down 5.7% on the NYSE. Analysts were surprised by the failure, as AstraZeneca is known for strong trial design. Rival companies Pfizer, BridgeBio Pharma, and Alnylam Pharmaceuticals saw initial stock gains. The article also contextualizes the sell-off within a broader market environment driven by extreme reactions to news, citing AI-related rallies and warnings about speculative behavior from Bank of America strategist Savita Subramanian.
Yahoo FinanceAstraZeneca stock dives 9% after heart drug trial misses target
Shares of AstraZeneca fell as much as 9% after a late-stage clinical trial for its experimental heart disease drug Wainua failed to meet its primary goal. The drug, intended to treat the rare and life-threatening condition transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), did not reduce deaths and recurrent heart-related emergencies over 140 weeks compared to a placebo. The British drugmaker announced the results in a press release on Thursday. The stock was last seen down 8.9% in London, on track for its worst single-day decline since March 2020 at the start of the Covid-19 pandemic.
US Top News and Analysis